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observe any statistical association between intratumoral
microvessel density (IMD), clinicopathological vari-
ables and p53 protein expression.
Key words: p53 protein – Angiogenesis – Morphome-
try – Prognosis – Nasopharyngeal carcinoma
Introduction
Nasopharyngeal carcinoma (NPC) is the most common
epithelial malignancy of the nasopharynx and is strong-
ly associated with the EBV virus [16, 34, 35]. Due to its
particular biologic behavior, patients in similar stages of
NPC demonstrate different clinical outcome and re-
sponses to the same treatment. In order to achieve a
more reliable prognostic evaluation of such patients, we
sought to identify other prognostic indicators that could
be used in conjunction with other well-established fac-
tors to obtain a better therapeutic approach.  
The p53 tumor suppressor gene is a regulator of nor-
mal cell growth and also plays an important role in the
apoptosis mechanism [14]. There is evidence that the p53
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Summary
The objective of this study was to evaluate the possible
prognostic significance of p53 protein overexpression
and tumor angiogenesis (TA) in nasopharyngeal carcino-
ma (NPC) patients, together with other clinicopathologi-
cal variables. Forty-two NPC patients were evaluated in
relation to survival. Nuclear p53 overexpression in neo-
plastic and endothelial cells was detected by immunohis-
tochemistry (IHC) with the monoclonal antibody DO-7
and the polyclonal antibody against factor VIII-related
antigen, respectively. Thereafter, we evaluated p53 cases
in order to determine their nuclear immunoreactivity
from negative (–) to positive (+, ++, +++). In addition,
microvessels were counted in the most active areas of
tumor neovascularization or hotspots using an image
computer analyzer (MicroImage®). 
A Cox multiple regression survival analysis was used
to determine the best prognostic indicators in NPC pa-
tients. As a result, tumor microvessel count, considered
as a continuous variable, was the most important inde-
pendent prognostic indicator in relation to survival
(p = 0.0273), with a relative risk of death of 2,4399
[95% confidence interval = 1.1051 ; 5.3871] associated
with the highest microvessel counts. Moreover, the only
clinicopathological variable that demonstrated prognos-
tic value in a Cox multiple regression survival analysis
was histological type (p = 0.05). In addition, we did not
protein is involved in the cell cycle by regulating the G1-S
transition after DNA damage [3]. This gene frequently
appears mutated in many different human tumors. For
this reason, the nuclear p53 phosphoprotein is very often
altered in the majority of such neoplasms [18]. The p53
mutated protein has a half-life increase, regarding the
wild type, that permits detection using IHC procedures
[6]. Overexpression of p53 protein revealed by IHC has
proven a reliable prognostic indicator in certain human
tumors [27], although some contradictory results exist
[39]. We evaluated the expression of p53 protein in order
to elucidate its possible prognostic role in NPC patients.     
Angiogenesis, the growth of new capillary blood ves-
sels, is on the other hand essential in normal processes
such as wound healing; it also has proven to be neces-
sary for the growth and metastatic spread of solid neo-
plasms [4, 11], including head and neck cancer. A frag-
mented basement membrane of newly-formed capillar-
ies increases the likelihood of tumoral cell invasion.
Moreover, several observations have proposed that IMD
is associated with overall survival in various tumor
types; further, in the past decade, angiogenesis has been
incorporated as a new prognostic indicator in the evolu-
tion of many malignant neoplasms [5, 11, 15, 21, 27, 29,
32, 37, 38]. 
Patients and Methods
Patients
In a retrospective study we examined tumor specimens from
54 patients with NPC (35 men and 19 women, mean age 49)
morphologically diagnosed and treated at University Hospital
La Fe between 1977 and 1994 at University Hospital La Fe.
Follow-ups ranged from 2 to 120 months (average 34 months).
Seven cases were excluded because they contained metastatic
tissue (13%), and 5 cases (9%) because of scanty tissular ma-
terial in original paraffin blocks. Hence, when this study was
carried out with 42 primary neoplasms, 29 patients had died
and 13 were alive. Histological diagnosis of the 42 cases was
done according to Micheau’s scheme [17], which accepts two
major microscopical types. Thus, 33 cases (79%) were consid-
ered as UCNT (undifferentiated carcinoma of nasopharyngeal
type) and 9 (21%) as SCC (squamous cell carcinoma). 
Antibodies
Tumoral cells were IHC stained using the DO-7 monoclonal
antibody (DAKO, Denmark) that recognizes an epitope in the
N-terminal of the human p53 protein between amino acids 35
and 45. This DO-7 antibody is highly recommended for retro-
spective studies on paraffin-embedded samples [9, 23, 31].
The DO-7 monoclonal antibody was diluted 1:100 and dis-
played by the streptavidin-biotin complex method [12]. Nega-
tive controls were carried out in every case by omitting the pri-
mary and secondary antibodies, respectively, from the IHC
procedure. Additionally, a p53-positive control was done with
a known p53-positive case. We evaluated p53 protein expres-
sion by the percentage of tumoral cells showing nuclear signal.
A case was labelled as positive when some tumoral cells
showed nuclear staining, and we assigned three positive
grades (+, ++, +++). We employed different positive grades
depending on the number of tumoral cells expressing p53 pro-
tein, and depending on their high or low  immunostaining.       
Intratumoral microvessels were highlighted by staining en-
dothelial cells using the polyclonal antibody against factor
VIII-related antigen (von Willebrand factor,  Biomeda Corp.,
USA). IHC staining was carried out by the streptavidin-biotin
complex method. It was thus possible to identify the most in-
tensely vascularized areas of the tumors. Negative controls
were done in every case by omitting the primary and sec-
ondary antibodies, respectively, from the IHC procedure. 
Immunohistochemistry (IHC)
IHC staining was done by the streptavidin-biotin complex
method. Formalin-fixed and paraffin-embedded 4µm-thick
sections were evaluated. Sections were dewaxed and mi-
crowave treated to retrieve the antigens. Later they were incu-
bated in 3% hydrogen peroxide in methanol for 10 min to block
endogenous peroxidase activity, followed by washing in phos-
phate-buffered saline PBS (Biomeda Corp., USA). Prediges-
tion of the tissue was carried out by incubating the sections for
10 min at 37 ºC in trypsin 1mg/ml PBS, then washing in PBS
for 5 min. Sections were then incubated in bovine serum albu-
min to reduce unspecific staining, followed by incubation with
the primary antibody for 30 min at room temperature. After
washing in PBS for 5 min, sections were incubated with bi-
otinylated secondary antibody (Dako, Denmark) and thereafter
incubated with streptavidin conjugated to horseradish peroxi-
dase at room temperature (Dako, Denmark). The peroxidase re-
action was developed using 3,3’diaminobenzidine tetrahy-
drochloride 5% as chromogen (Dako, Denmark), and sections
were counterstained with hematoxylin (Dako, Denmark).
Intratumoral microvessel density (IMD)
IMD was observed in areas of most intense neovascularization
or “hotspots” by scanning the tumor sections at low power (40 ×
and 100 ×) and identifying areas of invasive tumor with the
greatest number of discrete microvessel staining per area (Fig.
2). Microvessels were automatically counted using an image
computer analyzer on a 250 x field in the “hotspot”. An image of
each slide was captured digitally using a CCD camera connected
to an image computer analyzer (MicroImage®). The CCD cam-
era was attached to an Olympus CH-2 microscope. However, the
slide image captured by the computer had a field on the TV
screen of 0.5028 mm2. We then proceeded with RGB digital
color images, establishing the brown color range of the mi-
crovessel staining and selecting a single, countable microvessel
by computer. Any brown-staining endothelial cell or cell cluster
that was clearly separated from adjacent microvessels was con-
sidered as a single, countable microvessel. A vessel lumen was
not required for identification; microvessels with a greater diam-
eter (> 50 µm) were excluded from the study, in accordance with
Weidner et al. [38]. Each count was expressed as the highest
number of microvessels identified within any 250 × field. 
Statistics  
All statistical analyses were carried out using the SPSS-X sta-
tistical computer package (SPSS Inc, Chicago) for Windows
9.0. Univariate analysis by Student´s t test and Mann-Whitney
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method was used to assess differences between angiogenesis
in relation to clinicopathological variables and p53 expression.
A Chi-square test with Fisher´s correction was used for cate-
gorical variables to analyze the associations between p53 ex-
pression and clinicopathological variables. At the least, a Cox
multiple regression survival analysis was done to determine
the best independent prognostic indicators in NPC patients. A
p value less than 0.05 was considered significant [1, 13].
Results
p53 protein expression
p53 immunostaining was observed in the nuclei of tu-
moral cells (Fig. 1). Cases were labelled in different
groups according to their immunoreactivity intensity
and the number of p53-positive cells. We then evaluated
the p53 expression from negative  (–) to positive (+, ++,
+++). For better statistical study we created two groups
including negative (–) and low (+) p53 staining com-
pared to high p53 staining (++, +++). With respect to
p53 expression, four of the nine (44%) SCC cases
showed high (++, +++)  p53 staining. Moreover, all ad-
vanced IV-stage cases showed high p53 (++, +++) stain-
ing. Additionally, none of the 9 poor prognosis-SCC
cases was metastasis-positive. When a Cox multiple re-
gression survival analysis was done, p53 expression
failed to demonstrate any prognostic value (p = 0.9953).
Correlation between IMD and p53 expression
Mean and median values for IMD were 37 vessels.
Upon comparing IMD in relation to p53 expression, we
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Fig. 2. Microvessels stained for anti-von Willebrand factor
(Factor VIII) in a nasopharyngeal carcinoma biopsy. Intratu-
moral microvessel density (IMD) was determined in the most
intensely neovascularized area or “hotspots” (125×).
Fig. 1. Intense p53 immunostaining
observed in the nuclei of some tu-
moral cells in an undifferentiated
carcinoma case (UCNT) (200×).
did not observe any statistical association (p > 0.05).
Cases with p53 (–) and p53 (+, ++, +++) expression
were separated and compared with their microvessel
mean count; cases were also divided into negative or
low p53 staining (–, +) versus positive or high p53 stain-
ing (++, +++), and no statistical correlation was ob-
served in either case (Table 1).   
Angiogenesis correlated with
clinicopathological variables 
We analyzed certain clinicopathological variables, such
as tumoral type (UCNT and SCC), tumor size (T), stage
(I, II, III, IV), metastasis (M), sex and patient age (mean
and median = 49 years) in relation to angiogenesis. Sta-
tistical analysis was done using the Student´s t-test, plus
a non-parametric test (Mann-Whitney). Both methods
failed to reveal differences between clinicopathological
variables and microvessel count. Therefore, angiogene-
sis appears to be a possible independent factor apart
from histological type, size, stage, metastasis, sex and
age (Table 1).
Prognostic indicators in NPC patients
Furthermore, we used a multivariate analysis to deter-
mine the best prognostic indicators in NPC patients. The
multiple analysis was done by a Cox multiple regression
survival model, which revealed two significant prognos-
tic indicators of survival patients, namely histological
type (SCC-tumoral type had a poor prognosis compared
to UCNT, p = 0.05), and tumor microvessel count, con-
sidered as a continuous variable (p = 0.0273). As a re-
sult, angiogenesis was the most important independent
prognostic indicator in relation to survival, with a rela-
tive risk of death of 2,4399 [95% confidence interval =
1,1051;  5,3871] associated with the highest microvessel
counts (Table 2).
Discussion
We studied 42 NPC cases to establish a possibly signifi-
cant correlation between p53 expression, angiogenesis
and other clinicopathological variables in order to deter-
mine the best independent prognostic indicators in NPC
patients. 
p53 protein expression was observed in the nuclei of
tumoral cells. As was done in previons studies, cases
were divided into two groups according to their im-
munoreactivity intensity and number of p53-positive
cells [7, 9]. When a Cox multiple regression survival
analysis was done, p53 expression did not demonstrate
any prognostic value. However, other studies do show a
correlation between p53 expression and overall survival
in other tumoral types [7, 26], as in oral SCC cases [31].
Other reports show a statistical correlation between p53
gene mutation and overall survival, but without any cor-
relation when an IHC study was done. Wood et al. [39],
in SCC of the head and neck, reported that mutations of
the p53 gene determined by PCR-SSCP were signifi-
cantly associated with survival, but no significant asso-
ciation was observed when p53 expression was ana-
lyzed by IHC. In contrast, Rakozy et al. [23] reported
that p53 IHC study and not PCR-SCCP was associated
with survival in prostate cancer. These results demon-
strate that there is no perfect correlation between p53
gene mutations and the mutant protein expression. For
this reason, some authors conclude that p53 expression
in head and neck cancer is not a reliable predictor of sur-
vival [39].      
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Table 1. Correlation between tumor microvessel count, clini-
copathological variables and p53 expression
Variable Group No. Vessels*
Patients (mean group)
Histological Type UCNT 33 37
SCC 9 34
Tumor size T = 1/T = 2 15 31
T = 3/T = 4 27 39
Tumor stage I, II, III, 6 38
IV 36 36
Metastasis negative 30 35
positive 12 40
Sex men 26 34
women 16 40
Age ≥ 49 22 38
< 49 20 35
p53 expression (–) 29 37
(+, ++, +++) 13 37
(–, +) 33 37
(++, +++) 9 35
*Mann-Whitney method and Student´s t test (p > 0.05)
Table 2. Significant independent prognostic indicators in NPC
patient-related death
Multivariatic analysis*
Prognostic factor P-value Relative 95% CI2
risk1
Histological type 0.05 0.5363 (0.2789; 1.0315)
p 53 expression 0.9953 0.9976 (0.4488; 2.2176)
Microvessel count 0.0273 2.4399 (1.1051; 5.3871)
*Cox multiple regression survival analysis,
1of death associated with histological type, p53 expression or
microvessel count, 2confidence interval for relative risk.
When all microvessels were stained, angiogenesis
was assessed as density of microvessels in the most in-
tensively neovascularized areas or “hotspots” so as to
reflect the tumor activity and its development. Weidner
et al. [38] obtained the measure of angiogenesis through
the number of microvessels in the richest microvessel
density areas or “hotspots”. Moreover, the same authors
showed that patients with a high microvessel count had
a poor prognosis in relation to those with a low mi-
crovessel count [37]. Their findings revealed that the
probability of metastasis increases when the number of
microvessels does, which is in accordance with recent
results in the literature [10].
Upon comparing IMD with p53 expression, we did
not observe any statistical association; cases with p53(-)
and p53 (+, ++, +++) expression, and cases with nega-
tive or low p53 staining (–, +) versus positive or high
p53 staining (++, +++) were separated; we then com-
pared their mean microvessel count, and no statistical
correlation was observed under any circumstances. This
result is in accordance with Giatromanolaki et al. [9],
who showed no correlation between microvessel count
and p53 expression in non-small-cell cancer, but this re-
sult is in disagreement with other lung cancer [7] and
NPC reports [8]. Indeed, Gasparini et al., in SCC head
and neck cancer, did show a statistical correlation be-
tween these two biological markers in relation to metas-
tasis [8]. In our series 9 (21%) of 42 cases were SCC
cases, and none had tumor spread. Moreover, angiogen-
esis is considered an early event in the development of
an invasive tumor, in contrast to p53 mutations, consid-
ered a late event in head and neck cancer [8].  
With respect to the clinicopathological variables (his-
tological type, size, and stage of tumor, metastasis, sex
and age), the only independent prognostic indicator in
relation to survival in our study is histological type.
Hence, SCC tumoral type predicted poor prognosis
compared to UCNT; four of the nine (44%) SCC cases
showed a high (++, +++)  p53 staining. Further, four of
the nine cases with high (++, +++) p53 staining were
SCC cases. Thus, none of the 9 poor prognosis SCC
cases proved metastasis-positive; these differences can
help distinguish characteristics between SCC and
UCNT tumoral type.
We also observed a trend between p53 expression and
stage; all cases showing a high p53 (++, +++) staining
were stage IV (advanced). This result is in accordance
with previous studies [7, 9, 27, 31] showing a correla-
tion between p53-positive expression and advanced
tumor stage. On  the other hand, none of the SCC cases
was metastasis-positive. This result demonstrates that
angiogenesis is not only regulated by p53, but that other
angiogenesis factors are probably also implicated, such
as the expression of vascular endothelial growth factor
(VEGF) [9, 10, 36]. Moreover, mean tumor microvessel
count in SCC cases is not higher than in UCNT cases.
Thus, SCC poor prognosis cannot be explained by mi-
crovessel count. In our report no statistical differences
between clinicopathological variables and microvessel
number were detected, which is in accordance with sim-
ilar results in gastric cancer [27]. For this reason, angio-
genesis can be taken as an independent prognostic factor
apart from histological type, size and stage, as well as
from metastasis, sex, and age of patients. 
Alternatively, our multivariable study revealed that the
most important prognostic indicator in relation to survival
was tumor microvessel count, also in agreement with pre-
vious reports [7, 11, 27]. Consequently, angiogenesis is
the major prognostic indicator that could be routinely in-
corporated in the prognosis of NPC patients.
In conclusion, the image analyzer is an effective and
new tool with which to measure microvessels, thereby
enabling us to establish a reliable prognosis. Indeed, au-
tomatic analysis eliminates the major problem in this
kind of work, namely that of subjectivity. Controversial
results in angiogenesis studies would disappear if mor-
phometric studies were used routinely. Measuring an-
giogenesis may prove to be a further prognostic indica-
tor that can be used in conjunction with other well-es-
tablished factors, so as to achieve a more reliable prog-
nostic approach in NPC patients.  
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